Personalized prophylaxis in people with hemophilia A: challenges and achievements

被引:10
|
作者
Ar, Muhlis Cem [1 ]
Baslar, Zafer [1 ]
Soysal, Teoman [1 ]
机构
[1] Istanbul Univ, Div Hematol, Dept Internal Med, Cerrahpasa Med Fac, Istanbul, Turkey
关键词
Hemophilia; personalized prophylaxis; pharmacokinetics; hemophilic arthropathy; adherence; RECOMBINANT FACTOR-VIII; ON-DEMAND TREATMENT; TAILORED PROPHYLAXIS; CLINICIAN PERSPECTIVE; COST-EFFECTIVENESS; PHARMACOKINETICS; JOINT; ARTHROPATHY; MYPKFIT; HEALTH;
D O I
10.1080/17474086.2016.1252670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Prophylactic factor replacement is the standard of care for all people with severe hemophilia to prevent bleeding and associated complications. Current weight-based fixed dose prophylaxis regimens are effective; however, they lack flexibility and usually fail to meet the individual needs and expectations of the patients. Recent developments in hemophilia treatment provide new opportunities for a more personalized prophylaxis.Areas covered: Rationale and methods of individualizing prophylaxis in hemophilia A on the basis of current evidence are discussed in this review. For this relevant literature in English and German was searched using PubMed database.Expert commentary: Major determinants of personalized prophylaxis include age, bleeding pattern, personal pharmacokinetics, joint health, co-morbidities, venous access and adherence. An ideal prophylaxis programme should take into account all of the aforementioned items and also be able to meet the needs. Extended half-life factor concentrates, new hemostatic molecules and tools using population pharmacokinetics to estimate personal factor requirements will serve individualizing prophylaxis in a more precise manner.
引用
收藏
页码:1203 / 1208
页数:6
相关论文
共 50 条
  • [1] Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges
    Coppola, Antonio
    Tagliaferri, Annarita
    Di Capua, Mirko
    Franchini, Massimo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (01): : 79 - 94
  • [2] Personalized prophylaxis in patients with hemophilia in Argentina
    Baques, A.
    Sueldo, E.
    Guerrero, G.
    Do Nascimento, P.
    Arias, M. D. V.
    HAEMOPHILIA, 2018, 24 : 49 - 49
  • [3] Hemophilia-Therapy Optimization with personalized Prophylaxis
    Bischoff, Angelika
    HAMOSTASEOLOGIE, 2016, 36 (02): : 136 - 137
  • [4] Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives
    Bala, Natasha S.
    Thornburg, Courtney D.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2025, 51 (01): : 28 - 40
  • [5] Personalized Prophylaxis in Hemophilia a: A Pediatric Center Experience in Mexico
    Aquino, Efrain
    BLOOD, 2018, 132
  • [6] Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
    Chai-Adisaksopha, Chatree
    Nevitt, Sarah J.
    Simpson, Mindy L.
    Janbain, Maissaa
    Konkle, Barbara A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (09):
  • [7] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND INHIBITORS: A SYSTEMATIC REVIEW
    Camelo, R.
    Prudente, T. P.
    Minare, D. V.
    Gomes, G. D. P. V. C.
    Roberti, M. D. R. F.
    HAEMOPHILIA, 2023, 29 : 53 - 54
  • [8] Pharmacokinetics Using myPKFiTR for Personalized Prophylaxis in Children with Severe Hemophilia a.
    Nishimura, Shiho
    Tomioka, Keita
    Shimomura, Maiko
    Mizoguchi, Yoko
    Kobayashi, Masao
    BLOOD, 2017, 130
  • [9] The current challenges faced by people with hemophilia B
    Miesbach, Wolfgang
    von Drygalski, Annette
    Smith, Clive
    Sivamurthy, Krupa
    Pinachyan, Karen
    Bensen-Kennedy, Debbie
    Drelich, Douglass
    Kulkarni, Roshni
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (03) : 339 - 349
  • [10] COMPARISON OF PERSONALIZED AND STANDARD PROPHYLAXIS BASED ON OCTOCOG ALFA IN PEDIATRIC PATIENTS WITH HEMOPHILIA A
    Tatara, Tomasz
    Dabrowska-Bender, Marta
    Duda-Zalewska, Aneta
    Staniszewska, Anna
    Kurek, Magdalena
    ACTA POLONIAE PHARMACEUTICA, 2020, 77 (02): : 221 - 228